Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS - Full Text View

Purpose

Studies on the effect of sibutramine, an anti-obesity drug, on hormonal and metabolic features of women with polycystic ovary syndrome (PCOS) are lacking.

The objective of this study is to examine the effect of sibutramine plus hypocaloric diet on body composition, hormonal and metabolic parameters and insulin resistance in obese patients with PCOS.

Overweight and obese women with PCOS were placed in a hypocaloric diet plus sibutramine (10 mg/day) for the first month and then on a hypocaloric diet plus sibutramine (10 mg/day) or hypocaloric diet only for the subsequent 6 months.

The main outcome measures are: Body composition, hormonal and metabolic features and insulin sensitivity (OGTT) at baseline, at 3 and 6 months of treatment.

Condition	Intervention	Phase
Obesity Polycystic Ovary Syndrome	Drug: Sibutramine	Phase IV

MedlinePlus related topics:

Obesity Weight Control

Drug Information available for:

Sibutramine Sibutramine hydrochloride monohydrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Official Title:	Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS: a Randomized, 24-Week Study

Further study details as provided by Hippocration General Hospital:

Primary Outcome Measures:

weight loss

Secondary Outcome Measures:

FAI, insulin resistance and other metabolic parameters

Estimated Enrollment:	80
Study Start Date:	March 2004
Study Completion Date:	September 2006

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years to 40 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

overweight and obese women with PCOS

Exclusion Criteria:

Nonclassical 21-hydroxylase deficiency, hyperprolactinemia, adrenal or ovarian tumor and Cushing’s disease, hypertension, thyroid dysfunction, overt diabetes mellitus and concomitant treatment such as antihypertensive drugs, SSRI or other SNRI drug, oral contraceptive pills or any other antiandrogen treatment (cyproterone acetate, spirolactone, LHRH agonist) and insulin sensitizing agents (metformin, pioglitazone, roziglitazone) that may interact with insulin sensitivity and lipid profile.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00463112

Locations


Greece
	Hippocratio General Hospital
	Thessaloniki, Greece, 54642

Sponsors and Collaborators

Hippocration General Hospital

Investigators


Principal Investigator:	Dimos Florakis, MD	Divison of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Greece

More Information

Study ID Numbers:	511/8-1-04
First Received:	April 19, 2007
Last Updated:	April 19, 2007
ClinicalTrials.gov Identifier:	NCT00463112
Health Authority:	Greece: National Organization of Medicines

Keywords provided by Hippocration General Hospital:

Obesity

Polycystic Ovary Syndrome

weight loss

Hyperadrogonemia

Sibutramine

Study placed in the following topic categories:

Obesity

Gonadal Disorders

Endocrine System Diseases

Overweight

Ovarian Diseases

Cysts

Sibutramine

Body Weight

Genital Diseases, Female

Signs and Symptoms

Polycystic Ovary Syndrome

Weight Loss

Nutrition Disorders

Overnutrition

Endocrinopathy

Ovarian Cysts

Additional relevant MeSH terms:

Anti-Obesity Agents

Neoplasms

Pathologic Processes

Disease

Therapeutic Uses

Syndrome

Psychotropic Drugs

Appetite Depressants

Central Nervous System Agents

Antidepressive Agents

Pharmacologic Actions

Adnexal Diseases

ClinicalTrials.gov processed this record on November 20, 2008

Sponsored by:	Hippocration General Hospital
Information provided by:	Hippocration General Hospital
ClinicalTrials.gov Identifier:	NCT00463112